Active, not recruitingPHASE1, PHASE2NCT03770572
Gene Therapy for Children With CLN3 Batten Disease
Studying Batten Disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alcyone Therapeutics, Inc
- Principal Investigator
- Kathrin C Meyer, PhDAlcyone Therapeutics
- Intervention
- Low dose CLN-301(genetic)
- Enrollment
- 7 enrolled
- Eligibility
- 3-10 years · All sexes
- Timeline
- 2018 – 2029
Study locations (1)
- Nationwide Children's Hospital, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03770572 on ClinicalTrials.govOther trials for Batten Disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05228145Gene Therapy Study for Children With CLN5 Batten DiseaseNeurogene Inc.
- ACTIVE NOT RECRUITINGNCT04273243Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene TransferEmily de los Reyes
- ENROLLING BY INVITATIONNCT03862274Examining Developmental Outcomes of Children Diagnosed With CLN2 DiseaseJessica Scherr
- ACTIVE NOT RECRUITINGNCT03285425Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 DiseaeEmily de los Reyes
- RECRUITINGNCT01873924Clinical and Neuropsychological Investigations in Batten DiseaseUniversity of Rochester